回复@JZee: However, in a follow up report, WSJ said that the deal is unlikely to finalize before the pharma giant’s earnings date on July 28.The reasons for the delay are said to be an upcoming data readout for the Seagen’s (SGEN) bladder-cancer therapy Padcev and an impending outcome of a lawsuit between the company and Japanese drugmaker Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY) over royalty payments.//@JZee:回复@郁闷的_鞋套:他以前不是说还有个$Seagen(SGEN)$ 什么临床的readout么，已经读出来了么？我都忘了